Evozyne CEO Marc Yoskowitz is a veteran biopharma executive known for leading public and private companies through transformative periods of growth.

Prior to joining Evozyne, Yoskowitz was chief strategy officer and executive vice president of life sciences at Tempus AI. He has held executive leadership positions with Pfizer, Hospira and McKinsey & Company.

Yoskowitz has a lengthy track record of business building, P&L leadership, creative deal-making and strategic planning, with a deep reservoir of industry relationships. Over the course of his career, he has served as an operating executive, board member and advisor, leading global and domestic work across all facets of the biopharmaceutical value chain.He holds a JD from Columbia Law School.

Evozyne CSO Gary Krishnan is an experienced scientific leader with a career spanning more than 26 years in the biopharma industry.

Prior to joining Evozyne, Krishnan held multiple roles at Eli Lilly. Starting as a bench scientist, he spent over half his tenure in executive leadership positions, including Chief Scientific Officer for the Aging, Musculoskeletal, & Urology Research and Global Head of Translational Research for the Immunology business unit.

Krishnan has a successful track record in drug development, advancing more than a dozen assets into clinical testing and serving as a key contributor to four of Lilly’s blockbuster drugs. He also led the discovery of one of the world’s first therapies for hospitalized COVID-19 patients.

He holds a PhD in biochemistry and biophysics from Texas A&M University and completed his post-doctoral training at Baylor College of Medicine.

Arjun Rallapalli is focused on developing Evozyne’s overall strategy by identifying new markets, solutions, and services for the company’s proprietary technology and implementing the strategy through business development and partnerships. Before Evozyne, Rallapalli was a manager at McKinsey & Company, where he led strategy engagements across different sectors. He began his career at GE Healthcare before obtaining a PhD in electrical engineering at Duke University where he explored the possibility of creating photonic logic devices using DNA and organic molecules.

Uri Herzberg has extensive expertise in drug discovery with companies including Johnson & Johnson, Celgene, Cabaletta Bio, Celularity and Fresh Tracks Therapeutics. His expertise encompasses preclinical development, translational research, regulatory strategy, early clinical trial design target identification and indication selection. He holds a doctorate in veterinary medicine, a PhD in veterinary biology and neuroimmunology and an MBA in pharmaceutical development.